Additionally, dipeptidyl peptidase 4 (DPP-4) inhibitors, commonly used oral hypoglycemic agents, have been reported to alleviate potential cellular toxicities by increasing neurogenesis and preserving GLP-1 function in diabetic DC patients (26, 132). The gene discussed is DPP4; the disease is dyskeratosis congenita.